AbCellera Biologics

US · ABCL #2215 by market cap Listed 2020

12.83 -0.32 -2.43%

Live - 5344 symbols - heartbeat 481s ago · 2026-10-08 08:19

Pre-market 12.56 -2.10%

After-hours 12.85 +0.16%

Overnight 12.81 -0.16%

Market cap: 4.16B
P/E (TTM): -23.76
P/B: 4.64
EPS: -0.49
Div yield: 0.00%
52W pos: 82%

Reader sentiment Are you bullish or bearish on ABCL?

Anonymous reader poll. Unscientific, not investment advice.

About AbCellera Biologics

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Founded: 2012
CEO: Dr. Carl L.G. Hansen, PhD
Employees: 562
Headquarters: Vancouver, British Columbia, Canada
Fiscal year end: 12-31
Website: abcellera.com

Company profile

Exchange: US
Symbol: ABCL
Market-cap rank: #2215
Listing date: 2020-12-11
Market cap: 4.16B
Float cap: 2.83B
Shares out: 324.05M
Float shares: 220.93M

Sectors & themes

AI medical concept stocks Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 08:19:54 · For reference only, not investment advice and not tailored to your situation.